Ionis Pharmaceuticals Inc (IONS)
41.57
+0.01
(+0.02%)
USD |
NASDAQ |
Apr 16, 16:00
41.57
0.00 (0.00%)
After-Hours: 16:06
Ionis Pharmaceuticals Enterprise Value: 5.009B for April 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 15, 2024 | 5.009B |
| April 12, 2024 | 5.035B |
| April 11, 2024 | 5.146B |
| April 10, 2024 | 5.210B |
| April 09, 2024 | 5.194B |
| April 08, 2024 | 5.108B |
| April 05, 2024 | 5.251B |
| April 04, 2024 | 5.194B |
| April 03, 2024 | 5.332B |
| April 02, 2024 | 5.219B |
| April 01, 2024 | 5.356B |
| March 28, 2024 | 5.270B |
| March 27, 2024 | 5.461B |
| March 26, 2024 | 5.381B |
| March 25, 2024 | 5.351B |
| March 22, 2024 | 5.178B |
| March 21, 2024 | 5.182B |
| March 20, 2024 | 5.187B |
| March 19, 2024 | 5.096B |
| March 18, 2024 | 5.077B |
| March 15, 2024 | 5.153B |
| March 14, 2024 | 5.099B |
| March 13, 2024 | 5.242B |
| March 12, 2024 | 5.244B |
| March 11, 2024 | 5.257B |
| Date | Value |
|---|---|
| March 08, 2024 | 5.363B |
| March 07, 2024 | 5.462B |
| March 06, 2024 | 5.407B |
| March 05, 2024 | 5.392B |
| March 04, 2024 | 5.491B |
| March 01, 2024 | 5.577B |
| February 29, 2024 | 5.541B |
| February 28, 2024 | 5.735B |
| February 27, 2024 | 5.862B |
| February 26, 2024 | 5.671B |
| February 23, 2024 | 5.563B |
| February 22, 2024 | 5.362B |
| February 21, 2024 | 5.296B |
| February 20, 2024 | 5.416B |
| February 16, 2024 | 5.427B |
| February 15, 2024 | 5.551B |
| February 14, 2024 | 6.034B |
| February 13, 2024 | 5.968B |
| February 12, 2024 | 6.223B |
| February 09, 2024 | 6.371B |
| February 08, 2024 | 6.166B |
| February 07, 2024 | 6.102B |
| February 06, 2024 | 6.041B |
| February 05, 2024 | 6.086B |
| February 02, 2024 | 6.132B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.911B
Minimum
Dec 01 2021
10.20B
Maximum
Apr 16 2019
5.549B
Average
5.350B
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 4.084B |
| Viking Therapeutics Inc | 6.366B |
| Alnylam Pharmaceuticals Inc | 17.18B |
| Akero Therapeutics Inc | 977.32M |
| 89bio Inc | 333.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.263M |
| Revenue (Quarterly) | 324.50M |
| Total Expenses (Quarterly) | 330.62M |
| EPS Diluted (Quarterly) | -0.06 |
| Gross Profit Margin (Quarterly) | 99.06% |
| Profit Margin (Quarterly) | -2.85% |
| Earnings Yield | -6.16% |
| Normalized Earnings Yield | -7.312 |